Professor Charles Swanton, MB PhD FRCP FMedSci

Senior Group Leader, The Francis Crick Institute

Professor of Cancer Medicine, Translational Cancer Therapeutics Laboratory, University College London Hospitals and Cancer Institute

Chair in Personalised Medicine and Consultant Medical Oncologist

Director of Lung Cancer Centre of Excellence

London, United Kingdom


Professor Charles Swanton completed his MD PhD in 1999 at the Imperial Cancer Research Fund Laboratories and Cancer Research UK clinician scientist/medical oncology training in 2008.
Professor Charles Swanton combines his laboratory research at the Francis Crick Institute with clinical duties focused on biological mechanisms of cancer drug resistance.
Professor Charles Swanton was made Fellow of the Royal College of Physicians in April 2011 and Chair in Personalised Cancer Medicine and Consultant Thoracic Medical Oncologist at UCL Hospitals in November 2011.
Professor Charles Swanton is the Chief Investigator of the CR-UK TRACERx lung cancer evolution study and was awarded the Royal College of Physicians Goulstonian lecture and Graham Bull Prize for Clinical Sciences in 2013 and appointed Fellow of the European Academy of Cancer Sciences in 2013.
His interests are focused on cancer drug resistance and tumour evolution.  He has published over 120 papers, with first or senior author publications in the New England Journal of Medicine, Nature, Nature Genetics, Cancer Discovery, Cancer Cell, Science, Science Translational Medicine and the Lancet Oncology. His work has led to insight into genomic diversity within cancers (intratumour heterogeneity) and molecular mechanisms driving cancer branched evolution. His multidisciplinary team has discovered that DNA replication stress, cancer genome doubling events and the APOBEC cytidine deaminase family precipitate cancer diversity, accelerating cancer evolution, providing the substrate for cancer drug resistance and treatment failure.
Professor Charles Swanton was awarded the Stand Up 2 Cancer Laura Ziskin translational cancer research award in 2015 and the Biochemical Society 2016 GSK prize in recognition of distinguished research leading to new advances in medical science. He was made a Fellow of the Academy of Medical Sciences in 2015.

20th November 2015 (Friday) 17:15-17:45
Plenary Section I
Cancer Evolution: Implications for Early Phase Drug Development